Exploring the Growth of the Cancer Immunotherapy Market from 2025 to 2035

Gloabl Cancer Immunotherapy Market Size USD 245.37 Billion by 2032

The global cancer immunotherapy market is poised for substantial growth from 2025 to 2035, driven by significant advancements in biotechnology, the increasing prevalence of cancer, and a growing focus on personalized medicine. Unlike traditional treatments like chemotherapy, immunotherapy enhances the body’s immune system to target and eradicate cancer cells, offering a more targeted approach that reduces side effects while improving remission rates. The market is expected to exceed $165.81 billion by 2027, growing at a compound annual growth rate (CAGR) of 8.15%, and will continue to expand rapidly, surpassing $245.37 billion by 2032. The rising cancer burden worldwide, along with breakthroughs in immune checkpoint inhibitors, CAR-T cell therapies, and monoclonal antibodies, is driving this growth. Key players in this space, including Merck, Roche, and Bristol-Myers Squibb, are revolutionizing the treatment landscape and offering new hope for patients globally.

Cancer immunotherapy, a biological treatment that leverages the immune system, is gaining significant traction due to its ability to treat cancer with fewer side effects compared to traditional therapies. The focus on R&D, improvements in treatment efficacy, and rising cancer cases are driving market growth. Additionally, the financial impact of cancer on healthcare systems, particularly in the U.S., highlights the urgent need for innovative and more affordable cancer treatments.

Market Overview

The cancer immunotherapy market size, valued at $121.2 billion in 2023, is set to grow at a CAGR of 8.15%–11.6% through 2035. North America, holding a dominant market share of 44.4% in 2023, benefits from a robust healthcare infrastructure, high adoption of advanced therapies such as Keytruda and Opdivo, and favorable reimbursement policies. Meanwhile, the Asia-Pacific region is the fastest-growing market, with countries like China and India showing a strong growth trajectory due to increasing healthcare investments and improving regulatory frameworks.

Key factors driving this market’s growth include the rising cancer incidence globally. The World Health Organization (WHO) predicts the number of new cancer cases will rise from 19.29 million in 2020 to 24.58 million by 2030. Technological innovations, such as AI-driven drug discovery, biomarker research, and advancements in CAR-T therapies, are streamlining drug development and enhancing treatment efficacy. Furthermore, regulatory support from bodies like the FDA has expedited approval processes for cancer immunotherapy drugs, making these therapies more accessible to patients worldwide.

To learn more about the global trends impacting the future of Cancer Immunotherapy market research report, Download a PDF Sample

Key growth drivers include:

• Rising Cancer Burden: The World Health Organization (WHO) estimates 24.58 million new cancer cases by 2030, up from 19.29 million in 2020.
• Technological Innovations: AI-driven drug discovery, biomarker research, and next-gen CAR-T therapies are reducing development timelines and enhancing treatment efficacy.
• Regulatory Support: Expedited FDA approvals, such as quizartinib for acute myeloid leukemia (AML) and capivasertib for breast cancer, are accelerating market entry.

Market Dynamics

Several factors are propelling the growth of the cancer immunotherapy market, with rising cancer cases being the most significant driver. Lifestyle changes, an aging population, and genetic factors are contributing to an increase in cancer cases globally. According to the International Agency for Research on Cancer, cancer diagnoses are expected to reach 24.58 million by 2030, a significant rise from 19.29 million in 2020.

Innovation remains a critical opportunity for growth in the market. Continued research and development efforts are paving the way for advancements in targeted therapies, personalized treatments, and precision medicine. Partnerships, acquisitions, and collaborations among pharmaceutical giants and biotech startups are expected to further fuel these innovations and expand the market’s reach across new geographical regions.

From a technology standpoint, monoclonal antibodies remain the dominant segment, accounting for a significant share of the market in 2023. These antibodies are highly effective in targeting specific cancer cells and are generally safer with lower toxicity compared to chemotherapy. In addition, the checkpoint inhibitors segment is experiencing rapid growth due to their promising results in treating cancers like melanoma and lung cancer. By 2035, the global cancer immunotherapy market is expected to see increased adoption of CAR-T cell therapies, with these therapies expanding from blood cancers to solid tumors.

Drivers

1. Prevalence of Cancer: Lifestyle factors (smoking, obesity) and an aging population are increasing cancer incidence, necessitating advanced therapies.
2. Precision Medicine: Genomic sequencing and biomarkers enable tailored treatments, improving outcomes for conditions like NSCLC and melanoma.
3. Cost-Effective Biosimilars: Patent expirations of biologics (e.g., Avastin) are lowering costs, enhancing accessibility in low-income regions.

Restraints

1. High Treatment Costs: CAR-T therapies can exceed $500,000 per patient, limiting adoption despite payer programs.
2. Manufacturing Complexity: Personalized therapies like CAR-T require sophisticated logistics, posing scalability challenges.

Opportunities

1. Emerging Markets: Asia-Pacific and Latin America offer untapped potential due to improving healthcare infrastructure.
2. AI and Nanotechnology: AI optimizes mRNA vaccine design, while nanoparticle delivery systems enhance drug targeting.

Explore New Industry Opportunities – Download Your Sample Copy Now!

Ecosystem Analysis

The cancer immunotherapy ecosystem is composed of pharmaceutical giants, biotech startups, research institutions, and regulatory bodies, each playing a vital role in driving market growth. Leading pharmaceutical companies like Merck, Roche, and Novartis are investing heavily in R&D, producing high-impact treatments such as Keytruda, Tecentriq, and Opdivo, which have significantly contributed to market expansion.

Biotech startups like Immunocore and Iovance Biotherapeutics focus on niche cancer therapies, often in collaboration with larger firms for clinical trials and market access. Research institutions such as Memorial Sloan Kettering and the Tisch Cancer Institute are advancing cancer immunotherapy by leveraging AI models like SCORPIO to predict treatment outcomes and improve patient care.

Regulatory bodies, including the FDA, continue to play a critical role by fast-tracking the approval of promising immunotherapy drugs. Notably, the Breakthrough Therapy Designation expedites the review process for drugs like durvalumab, which has shown promising results in treating cancers such as biliary tract cancer.

The immunotherapy ecosystem comprises:

1. Pharmaceutical Giants: Roche, Merck, and Novartis invest heavily in R&D, with Roche’s Tecentriq and Merck’s Keytruda leading revenue streams.
2. Biotech Startups: Companies like Immunocore and Iovance Biotherapeutics focus on niche therapies, often partnering with larger firms for clinical trials.
3. Research Institutions: Memorial Sloan Kettering and the Tisch Cancer Institute collaborate on AI models (e.g., SCORPIO) to predict treatment outcomes.
4. Regulatory Bodies: The FDA’s Breakthrough Therapy Designation fast-tracks promising drugs, such as durvalumab for biliary tract cancer in China.

The global Cancer Immunotherapy market can be categorized as Product, Application, Distribution Channel, End Use, and Region.

The global cancer immunotherapy market is segmented by product, application, and end user, with monoclonal antibodies leading the market in 2023, holding a 66.8% revenue share. These antibodies, including PD-1/PD-L1 inhibitors like Keytruda, are effective in treating various cancers with minimal side effects. The CAR-T cell therapy segment is projected to grow rapidly, fueled by expanding research into blood cancers and the emerging use of these therapies in solid tumors.

In terms of application, lung cancer holds the largest share of the market, driven by high mortality rates and the increasing adoption of immunotherapies. The breast cancer segment, however, is expected to grow at the fastest rate due to the rising number of diagnoses and ongoing research into novel treatments for this prevalent cancer.

End users include hospitals and clinics, which accounted for nearly 50% of the market in 2023, and cancer research centers, which are expected to register significant growth due to increased government and corporate investment in cancer research and treatment innovations.

Segmentation

By Product:

• Monoclonal Antibodies (55.9% market share): Dominated by PD-1/PD-L1 inhibitors like Keytruda.
• CAR-T Cell Therapy: Expanding from blood cancers to solid tumors, projected to grow at 11.8% CAGR.

By Application:

• Lung Cancer (13.8% share): Driven by smoking and e-cigarette use.
• Breast Cancer (Fastest-growing): Fueled by 2.3 million new cases globally in 2020.

By End User:

• Hospitals & Clinics (49.8% share): High adoption due to advanced infrastructure.
• Online Pharmacies: Growing at 11.27% CAGR, supported by telemedicine trends.

Buy this Premium Research Report:– Purchase Now

Recent Developments

Several key developments have marked significant progress in the cancer immunotherapy market. In January 2025, an AI model named SCORPIO was developed to predict immunotherapy outcomes more affordably, potentially revolutionizing personalized cancer treatments. The FDA also approved Talvey for the treatment of relapsed multiple myeloma in August 2023, adding a new weapon to the arsenal of cancer immunotherapies.

Strategic collaborations have also been crucial in advancing the field. For instance, CytoMed and SunAct partnered to conduct trials in India, while Immatics and Moderna are exploring combination therapies to enhance treatment efficacy. These collaborations highlight the growing trend of partnerships between large pharma and biotech companies to accelerate the development of new cancer treatments.

• AI Innovations: In January 2025, SCORPIO, an AI model, was developed to predict immunotherapy outcomes affordably.
• Regulatory Approvals: The FDA approved Talvey for relapsed multiple myeloma in August 2023.
• Strategic Collaborations: CytoMed and SunAct partnered for trials in India, while Immatics and Moderna explored combination therapies.

Browse in-depth TOC on "Global Cancer Immunotherapy Market Size"

Competitive Landscape

The competitive landscape of the cancer immunotherapy market is defined by both established pharmaceutical giants and emerging biotech firms. Merck, Roche, and Bristol-Myers Squibb are the dominant players, with groundbreaking therapies like Keytruda, Tecentriq, and Opdivo leading the market. These companies continue to expand their portfolios through investments in R&D and strategic acquisitions.

Emerging companies such as Immunocore and Adaptimmune are gaining ground with their novel T cell receptor therapies, which are challenging the traditional immunotherapy approach. The market is also experiencing increased mergers and acquisitions as companies seek to enhance their pipelines and global reach. For example, Boehringer Ingelheim's acquisition of Nerio Therapeutics for $1.3 billion illustrates the ongoing consolidation in the industry.

The market is highly consolidated, with the top 5 players holding ~45% share. Key strategies include:

• Mergers & Acquisitions: Boehringer Ingelheim acquired Nerio Therapeutics for $1.3 billion to bolster its immuno-oncology pipeline.
• R&D Investments: Pfizer’s MEKTOVI + BRAFTOVI combo received FDA approval for NSCLC in 2023.
• Geographic Expansion: AstraZeneca and Roche are targeting Asia-Pacific through local partnerships.

To know about the vendor offerings - Request a sample report

Conclusion and Future Outlook

The cancer immunotherapy market is set to redefine oncology care, thanks to innovations like AI-driven personalization and cost-reduction strategies. Challenges such as high treatment costs and manufacturing complexities will persist, but advancements in gene editing technologies like CRISPR and the development of oncolytic viruses hold the promise of overcoming these hurdles. By 2035, the market is expected to exceed $500 billion, with North America and Asia-Pacific leading the charge in adoption.

To fully realize the potential of cancer immunotherapy, stakeholders must prioritize sustainability, affordability, and continued collaboration in research and development. As the market evolves, the focus will shift to making these life-saving therapies accessible to a broader global population, further accelerating the fight against cancer.